SABCS 2022 Conference Coverage
Playback speed
10 seconds
SABCS 2022 Primary Results of the Randomized Phase 3 DESTINY-Breast02 Study: T-DXd vs. Physician’s Choice in HER2+ Unresectable and/or mBC Previously Treated With Trastuzumab Emtansine
By
SABCS 2022 Conference Coverage
FEATURING
Ian Krop
By
SABCS 2022 Conference Coverage
FEATURING
Ian Krop
147 views
January 5, 2023
Login to view comments.
Click here to Login
Videos